CXCL10 Identified as Response Biomarker for Ruxolitinib Cream in Vitiligo
CXCL10 correlates with clinical response to ruxolitinib cream in vitiligo, per the Phase 2 TRuE-V mechanism-of-action study published October 13, 2026, in JID.
Topic
Ruxolitinib
Topic
Ruxolitinib
Topical or Oral JAK Inhibitors for Vitiligo: The Choice Problem
Dermatology Times examines how clinicians should choose between topical and oral JAK inhibitors for vitiligo as systemic options…
Medscape Tackles Topical Therapy Optimization in Atopic Dermatitis
Medscape has published 'Optimizing Topical Therapy for Atopic Dermatitis,' addressing real-world prescribing as crisaborole, ruxo…
Ruxolitinib Clears Steroid-Refractory Sweet Syndrome in PV Case
A Swiss case report shows ruxolitinib cleared steroid-refractory histiocytoid Sweet syndrome in six weeks in a PV patient already…